1 Ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK Report commissioned by: NIHR HTA Programme On behalf of: The National Institute for Health and Clinical Excellence (NICE) Produced by: Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, University of Exeter Authors: Martin Hoyle, Research Fellow, PenTAG, University of Exeter Louise Crathorne, Associate Research Fellow, PenTAG, University of Exeter Tiffany Moxham, Information Scientist, PenTAG, University of Exeter Ruth Garside, Senior Research Fellow, PenTAG, University of Exeter Chris Hyde, Professor of Public Health and Clinical Epidemiology, PenTAG, University of Exeter Correspondence to: XXXX XXXX PenTAG Peninsula College of Medicine and Dentistry Veysey Building Salmon Pool Lane Exeter EX2 4SG XXXX XXXX@pcmd.ac.uk Date completed: 6 April 2010 Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.